The nation of Zimbabwe has declined a significant US healthcare agreement valued at $367m (272 million pounds) spanning five years because of Washington's demand for sensitive biological samples.
This rejection became public following a government memo from December was leaked, which showed Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
An official spokesperson has since clarified that the United States was requesting health data for research and commercial purposes but was not willing to guarantee the benefits from any future vaccines.
"We are forced to start the difficult and regrettable process of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for more talks to find a agreement suitable to both sides so the nation's critical HIV treatment initiative can proceed.
Wider Implications
Zimbabwe's decision comes after a comparable case in Kenya, where a high court halted a related deal with the US after legal challenges were filed about the security of citizens' medical information.
Since resuming office last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump stated its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to enhance transparency and responsibility.
Based on statements, Sixteen nations in Africa have to date agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to share its genetic material and health information indefinitely, with no equivalent promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"Effectively, our nation would provide the basic resources for medical research without any assurance that the resulting innovations would be available to our citizens if a new health crisis emerge."
National Interest and Global Health
He also noted that the US's withdrawal from the global health body and its pursuit of one-on-one deals were upending structures already established via the global organization.
Mangwana cited its Pandemic Benefit-Sharing scheme created to manage future global health emergencies.
"This system is intended to guarantee that when a country provides its data, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We are open to further dialogue with our American counterparts on how future co-operation could be designed in a way that respects the independence and dignity of each country."
Health Experts Reaction
Medical experts said it understood the official position, but urged that talks need to persist given that a large portion of the nation's Aids initiatives depended on foreign aid.
"If technical issues arise, including those involving data governance or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," the group added.
The halted deal emphasises the ongoing challenges between receiving crucial international aid and safeguarding a country's data in an ever more interconnected world.